[go: up one dir, main page]

WO2001005821A3 - Utilisations de l'il-10 virale - Google Patents

Utilisations de l'il-10 virale Download PDF

Info

Publication number
WO2001005821A3
WO2001005821A3 PCT/EP2000/006558 EP0006558W WO0105821A3 WO 2001005821 A3 WO2001005821 A3 WO 2001005821A3 EP 0006558 W EP0006558 W EP 0006558W WO 0105821 A3 WO0105821 A3 WO 0105821A3
Authority
WO
WIPO (PCT)
Prior art keywords
viral
metastasis
angiogenesis
tumorigenesis
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/006558
Other languages
English (en)
Other versions
WO2001005821A2 (fr
Inventor
Maria Teresa Bejarano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU58270/00A priority Critical patent/AU5827000A/en
Publication of WO2001005821A2 publication Critical patent/WO2001005821A2/fr
Publication of WO2001005821A3 publication Critical patent/WO2001005821A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne divers procédés relatifs à l'utilisation de l'IL-10 virale, et en particulier le fait que l'IL-10 virale est capable d'inhiber l'angiogenèse, l'action tumorigène et la métastase.
PCT/EP2000/006558 1999-07-16 2000-07-11 Utilisations de l'il-10 virale Ceased WO2001005821A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU58270/00A AU5827000A (en) 1999-07-16 2000-07-11 Viral il-10 uses

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35483399A 1999-07-16 1999-07-16
US09/354,833 1999-07-16
US16362799P 1999-11-04 1999-11-04
US60/163,627 1999-11-04

Publications (2)

Publication Number Publication Date
WO2001005821A2 WO2001005821A2 (fr) 2001-01-25
WO2001005821A3 true WO2001005821A3 (fr) 2001-07-19

Family

ID=26859813

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/006558 Ceased WO2001005821A2 (fr) 1999-07-16 2000-07-11 Utilisations de l'il-10 virale

Country Status (2)

Country Link
AU (1) AU5827000A (fr)
WO (1) WO2001005821A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1324779B1 (fr) 2000-09-29 2011-07-20 Schering Corporation Interleukine 10 pegylee
WO2002066069A1 (fr) * 2001-02-20 2002-08-29 Kansai Technology Licensing Organization Co., Ltd. Remedes contre l'inflammation/les maladies tumorales
AU2007314501B2 (en) 2006-09-28 2013-05-23 Merck Sharp & Dohme Corp. Use of pegylated IL-10 to treat cancer
EP2379115B1 (fr) 2008-12-17 2017-10-25 Merck Sharp & Dohme Corp. Production d'il-10 mono- et di-pégylé et ses utilisations
HK1215681A1 (zh) 2013-04-18 2016-09-09 Armo Biosciences, Inc. 使用白细胞介素-10治疗疾病和病症的方法
ES2688206T3 (es) 2013-06-17 2018-10-31 Armo Biosciences, Inc. Procedimiento de evaluación de la identidad y la estabilidad de proteínas
CN105658232A (zh) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
ES2862139T3 (es) 2013-11-11 2021-10-07 Armo Biosciences Inc Procedimientos de uso de Interleucina 10 para el tratamiento de enfermedades y trastornos
US10293043B2 (en) 2014-06-02 2019-05-21 Armo Biosciences, Inc. Methods of lowering serum cholesterol
KR20170068553A (ko) 2014-10-14 2017-06-19 아르모 바이오사이언시스 인코포레이티드 인터류킨-15 조성물 및 이의 용도
MX2017004983A (es) 2014-10-22 2017-11-13 Armo Biosciences Inc Metodos para usar interleucina 10 para tratar enfermedades y trastornos.
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
HK1248137A1 (zh) 2015-05-28 2018-10-12 阿尔莫生物科技股份有限公司 用於治疗癌症的聚乙二醇化白细胞介素-10
MX2018002298A (es) 2015-08-25 2018-07-06 Armo Biosciences Inc Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012725A1 (fr) * 1991-01-16 1992-08-06 Schering Corporation Traitement de maladie neoplastique a l'interleukine 10
US5770190A (en) * 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012725A1 (fr) * 1991-01-16 1992-08-06 Schering Corporation Traitement de maladie neoplastique a l'interleukine 10
US5770190A (en) * 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BENJAMIN DAVID: "Interleukin-10 (IL-10)", CANCER TREATMENT RESEARCH, vol. 80, 1995, pages 305 - 319, XP000979179 *
BERMAN ROBERT M ET AL: "Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice.", JOURNAL OF IMMUNOLOGY, vol. 157, no. 1, 1996, pages 231 - 238, XP002158947, ISSN: 0022-1767 *
CERVENAK LASZLO ET AL: "Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by interleukin-10.", BLOOD, vol. 96, no. 7, 1 October 2000 (2000-10-01), pages 2568 - 2573, XP002159072, ISSN: 0006-4971 *
DE WAAL MALEFYT R ET AL: "THE BIOLOGY OF HUMAN AND VIRAL IL-10", CYTOKINE, vol. 3, no. 5, 1991, pages 500, XP002158949, ISSN: 1043-4666 *
HUANG SUYUN ET AL: "Interleukin 10 Suppresses Tumor Growth and Metastasis of Human Melanoma Cells : Potential Inhibition of Angiogenesis", CLINICAL CANCER RESEARCH, vol. 2, no. 12, December 1996 (1996-12-01), pages 1969 - 1979, XP000979204 *
KUNDU NAMITA ET AL: "Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer.", JOURNAL OF THE NATIONAL CANCER INSTITUTE (BETHESDA), vol. 88, no. 8, 1996, pages 536 - 541, XP000979212, ISSN: 0027-8874 *
RICHTER GUENTHER ET AL: "Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration.", CANCER RESEARCH, vol. 53, no. 18, 1993, pages 4134 - 4137, XP002158948, ISSN: 0008-5472 *
STEARNS M E ET AL: "IL-10 inhibition of human prostate PC-3 ML cell metastases in SCID mice: IL-10 stimulation of TIMP-1 and inhibition of MMP-2/MMP-9 expression.", INVASION & METASTASIS, vol. 17, no. 2, March 1997 (1997-03-01), pages 62 - 74, XP000979206, ISSN: 0251-1789 *
STEARNS MARK ET AL: "Interleukin 10 (IL-10) Inhibition of Primary Human Prostate Cell-induced Angiogenesis : IL-10 Stimulation of Tissue Inhibitor of Metalloproteinase-1 and Inhibition of Matrix Metalloproteinase (MMP)-2/MMP-9 Secretion", CLINICAL CANCER RESEARCH, vol. 5, January 1999 (1999-01-01), pages 189 - 196, XP000979198 *

Also Published As

Publication number Publication date
AU5827000A (en) 2001-02-05
WO2001005821A2 (fr) 2001-01-25

Similar Documents

Publication Publication Date Title
ZA993364B (en) Novel 4-phenylpiperidines for the treatment of pruritic dermatoses.
ZA991951B (en) Compound and its use.
ZA991975B (en) Enzyme inhibitors.
AU2002214276A1 (en) Silicon carbide based porous article and method for preparing the same
MXPA02012188A (es) Metodo y sistema de barrenado multi gradiente.
ZA200201806B (en) Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof.
MXPA03000638A (es) Sujetador de tapetes de espuma, continuo, y metodo para utilizarlo.
AU1756799A (en) Epoxidation catalyst, its use and epoxidation method in the presence of said catalyst
ZA991953B (en) Detection of fermentation-related microorganisms.
GB9817055D0 (en) Reverse transcription and amplification processes and primers therefore
WO2001005821A3 (fr) Utilisations de l'il-10 virale
MXPA01011145A (es) Metodo para la conservacion de virus y micoplasma.
IL140927A0 (en) Perforator for weblike materials with means for modifying the interval between consecutive lines of perforations
AU8661201A (en) Method, system and shoe enabling the determination of fit from outside of the shoe
MXPA01009950A (es) Sistema de manejo de material y metodo para operar el mismo.
AU2581700A (en) Sandfilter device for use in the recovery of oil, gas and water
ZA200110474B (en) Method and device for the continuous of NaAlCl4 or NaFeCl4.
IL156162A0 (en) Coniosetin and derivatives thereof, method for producing the same and use thereof.
AU2001251631A1 (en) Hydrazide and alkoxyamide angiogenesis inhibitors
AU2002227966A1 (en) Coniosetin and derivatives thereof, method for producing the same and use thereof
AU2001283336A1 (en) Selective urokinase inhibitors
ZA200109120B (en) Use of Arylalkanoylpyridazines.
AU2002226301A1 (en) Organic semiconductor, production method therefor and the use thereof
GB2334100A8 (en) Chromogenic substrates, media and methods for the detection of salmonella spp.
MXPA03003524A (es) Un producto absorbente y el procedimiento para fabricacion de un producto absorbente.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP